Discoidin Domain Receptor 2: A New Target in Cancer
Background: Discoidin domain receptor is a new and unique type of receptor tyrosine kinases, which binds to collagen, the main compose of an extracellular matrix. DDR1 was identified to mediate cell aggregation, and dysregulation of DDR2 has also been shown to be involved in tumor pathogenesis, although its role in cancer development and progression remains controversial.Summary: Abnormal expression and mutations of DDR2 have been reported in several cancer types and its participation in different aspects of tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and ...
Source: Oncology Research and Treatment - January 24, 2022 Category: Cancer & Oncology Source Type: research

A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
Conclusion The rapid change of the treatment landscape, the limited use of BEV/IFN in 1st line and the durati on of 1st line treatment jeopardized BERAT trial recruitment. The small number of patients is a major limitation of our trial. Our observation indicated the poor prognosis in progressive patients and the limited efficacy of TKI or mTOR inhbitors in 2nd line treatment. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 19, 2022 Category: Cancer & Oncology Source Type: research

Bone Infarct Associated Osteosarcoma: Epidemiologic and Survival Trends
Conclusions Based on this work, our opinion is that the choice to undergo the patients to ChT combined to surgery could improve their prognosis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 14, 2022 Category: Cancer & Oncology Source Type: research

Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated With Concurrent Chemoradiation: A Multicenter Study
In this study, we analyzed the efficacy of AC after CCRT in stage III CC patients. Methods: We performed a multicenter, retrospective analysis of 139 FIGO stage III CC patients treated with CCRT of whom 45.3% received AC. Our goal was to determine the impact of AC on survival in these patients. Results: Five-year progression-free survival was 37.5% and 16% in patients receiving CCRT with and without AC, respectively (p=0.008). Median PFS was 30.9 months (CI 95 %14.8-46.9) and 16.6 months (CI 95% 9.3-23.9) in patients receiving CCRT with and without AC, respectively. Five-year overall survival was 78.2% and 28.4% in patie...
Source: Oncology Research and Treatment - January 14, 2022 Category: Cancer & Oncology Source Type: research

Preliminary Clinical Validation of a Filtration-Based CTC Assay for Tumor Burden and HER2 Status Monitoring in Metastatic Breast Cancer
Conclusion: The preliminary results from this study suggest promise for the interrogated CDC assay in several aspects, including sensitive CTC detection, accurate disease status reflection, and HER2 status determination. More studies are warranted to validate these findings and further characterize the value of CTC assay.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 11, 2022 Category: Cancer & Oncology Source Type: research

Risk and Prognosis of Subsequent Primary Gastric Cancer
Introduction: The incidence and prognostic impact of subsequent primary gastric cancer (GC) in a population of other cancer survivors is unclear. We aimed to evaluate susceptibility to subsequent primary GC in cancer survivors and prognosis of GC with prior cancer history. Methods: 2,211 and 23,416 GC cases with and without prior cancer history were retrospectively selected from the Surveillance, Epidemiology and End Results (SEER) database. Potential risk of developing subsequent primary GC was assessed through standardized incidence ratios (SIRs). Cox regression were adopted to analyze the influence of prior cancer hist...
Source: Oncology Research and Treatment - January 9, 2022 Category: Cancer & Oncology Source Type: research

Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach
Background Management of Raswild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge. Development of treatment resistance with prevalence of pre-existing RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. Summary The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the ...
Source: Oncology Research and Treatment - January 9, 2022 Category: Cancer & Oncology Source Type: research

The Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients
Background: Breast cancer is still the most common malignancy in women worldwide. Once metastasized, breast cancer treatment primarily aims at reducing symptom burden, thereby trying to maintain and improve a patient ´s quality of life (QoL), delaying disease progression, and prolonging survival. Curing the disease is not possible in the palliative setting. To better understand metastatic breast cancer patients, their symptoms and wishes, which are important for treatment-decision making and outcome, patient-re ported outcomes (PROs) are of great importance, giving an impression of what really matters to and concerns...
Source: Oncology Research and Treatment - January 9, 2022 Category: Cancer & Oncology Source Type: research

Supportive Care Needs and the Impact of Loss of Functioning and Symptom Burden on the Quality of Life in Patients with Advanced Colorectal Cancer
Conclusions Significant links between CRC-related loss of functioning, symptom burden, QoL and supportive care needs have been established. Longitudinal studies are planned to clarify cause-and-effects relationships and establish sequences of events. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 4, 2022 Category: Cancer & Oncology Source Type: research

The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Conclusion: The boron-based gel has a significant preventive effect on several categories of RD which might be used by clinicians in breast cancer.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 3, 2022 Category: Cancer & Oncology Source Type: research

Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study
Introduction: Cancer-associated venous thrombosis (CAT) is a common and serious complication of active malignancies, increasing in frequency during systemic treatment and radiotherapy. Due to a high risk of recurrence and bleeding, the administration of anticoagulants for initial treatment and secondary prevention of CAT is challenging. We conducted a prospective registry study of patients with acute CAT to evaluate the way treatment is given to these patients in routine practice. Methods: From May 2015 to May 2017, all consecutive patients with acute venous thromboembolism (VTE) admitted to specialty or emergency departm...
Source: Oncology Research and Treatment - December 28, 2021 Category: Cancer & Oncology Source Type: research

Antibody-Drug Conjugates for Breast Cancer
Background: Despite the advances that have been made to improve conventional chemotherapies, their use is limited by a narrow therapeutic window based on off-target toxicities. Antibody-drug conjugates (ADCs) are composed of an antibody and a toxic payload covalently coupled by a chemical linker. They constitute an elegant means to tackle the limitations of conventional chemotherapeutics by selectively delivering a highly toxic payload directly to target cells and thereby increasing efficacy of the delivered cytotoxic but at the same time limiting systemic exposure and toxicities. As such, they appear inspired by Paul Ehrl...
Source: Oncology Research and Treatment - December 16, 2021 Category: Cancer & Oncology Source Type: research

Antibody-Drug-Conjugates for Breast Cancer
Background Despite the advances that have been made to improve conventional chemotherapies, their use is limited by a narrow therapeutic window based on off-target toxicities. Antibody-drug-conjugates (ADCs) are composed of an antibody and a toxic payload covalently coupled by a chemical linker. They constitute an elegant means to tackle the limitations of conventional chemotherapeutics by selectively delivering a highly toxic payload directly to target cells and thereby increasing efficacy of the delivered cytotoxic but at the same time limiting systemic exposure and toxicities. As such they appear inspired by Paul Ehrl...
Source: Oncology Research and Treatment - December 16, 2021 Category: Cancer & Oncology Source Type: research

Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin and Docetaxel within the CEFCID Trial
Conclusion: Therapy intensification not adversely affect selected scores of QoL of patients with recurrent and/or metastatic SCCHN. Nevertheless, fatigue seems to be pronounced in patients treated with docetaxel. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 10, 2021 Category: Cancer & Oncology Source Type: research

New Opportunities in Advanced Breast Cancer
n/a (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 10, 2021 Category: Cancer & Oncology Source Type: research

Erratum
Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 10, 2021 Category: Cancer & Oncology Source Type: research

Radiofrequency Thermoablation and Hypofractionated Radiotherapy Combined Treatment for Bone Metastases: A Retrospective Study
Conclusion: The results of this retrospective analysis of patients treated with RFA-RT combined approach for BP support its safety and efficacy in terms of pain reduction. SBRT role in this combined approach has to be investigated in randomized trials.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 8, 2021 Category: Cancer & Oncology Source Type: research

PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation
Conclusion: Colorectal cancer is a clinically and molecularly heterogenic disease which requires comprehensive genetic testing to screen for r are genetic alterations like POLE mutations to detect tumors harboring an ultramutator phenotype especially in patients that are refractory to standard chemotherapy. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 7, 2021 Category: Cancer & Oncology Source Type: research

The Study of Cerebral Blood Flow Variations during Brain Metastases Radiotherapy
Conclusion: CBF changes can be feasibly assessed in different brain regions during RT based on 3D-ASL. The changes should be considered as a critical factor to determine the personal radiation dose for BMs, normal brain tissue, and peritumoral edema areas. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 7, 2021 Category: Cancer & Oncology Source Type: research

The Study of Cerebral Blood Flow Variations during Brain Metastasis Radiotherapy
Purpose: To investigate the cerebral blood flow (CBF) variations during brain metastases (BMs) radiotherapy (RT) applying with MR 3D-arterial spin labeling (ASL). Materials and Methods: A total of 26 BMs patients with 54 tumors were retrospectively enrolled. MR examinations were performed before and during RT (30-50 Gy) with a total dose of 36-60 Gy (12-30 fractions) including contrast-enhanced T1-weighted, T2 Flair and 3D-ASL images. The relationship between CBF changes and the largest  cross-sectional area changes in BMs was investigated. And CBF changes in BMs, normal brain tissue, and peritumoral edema areas...
Source: Oncology Research and Treatment - December 7, 2021 Category: Cancer & Oncology Source Type: research

Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer – a Monocenter Retrospective Cohort Study
Background aims: While irresectable pancreatic cancer has still a dismal overall prognosis, evidence about the optimal chemotherapy sequence is scarce. After treatment with FOLFIRINOX in first-line, Gemcitabine-monotherapy was established for years. As a potential treatment alternative after failure of FOLFIRINOX therapy, combination of Gemcitabine and Nab-Paclitaxel is used. However, this combination has formally not yet been approved for second-line treatment and investigation of efficiency and treatment tolerance is the aim of this trial. Methods: Therefore, we investigated 225 patients with histologically confirmed lo...
Source: Oncology Research and Treatment - December 7, 2021 Category: Cancer & Oncology Source Type: research

Contents Vol. 44, 2021
Oncol Res Treat 2021;44:I –X (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Oncol Res Treat 2021;44:719 –720 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

Society Bulletins
Oncol Res Treat 2021;44:737 –744 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

PharmaNews
Oncol Res Treat 2021;44:732 –736 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

PharmaNews
Oncol Res Treat 2021;44:730 –731 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

PharmaNews
Oncol Res Treat 2021;44:728 –729 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

PharmaNews
Oncol Res Treat 2021;44:727 –727 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

Effektive Erstlinien-Behandlung bei SCCHN mit Cetuximab-basierten Chemotherapie-Regimen
Oncol Res Treat 2021;44:721 –726 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

OnkoImmun 15
Oncol Res Treat 2021;44:I –XII (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 3, 2021 Category: Cancer & Oncology Source Type: research

Comparative Analysis of Postoperative Complications after Cytoreductive Surgery and HIPEC in Gastric Cancer
Conclusion: CRS and HIPEC do not lead to an increased postoperative morbidity and mortality in AGC with PC. Albeit the poorer prognosis of patients with PC, survival of both groups was comparable.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 29, 2021 Category: Cancer & Oncology Source Type: research

Family Formation and Socio-Economic Status among 35-Year-Old Men Who Have Survived Cancer in Childhood and Early Adulthood: A Register-Based Cohort Study
Conclusion: Many men who have survived cancer during childhood or early adulthood are influenced by their cancer later in life, which was apparent in family formation, educational achievements, and labour market attachment. Continued focus on rehabilitation and needs for support among the male survivors of childhood and youth cancer is warranted.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 25, 2021 Category: Cancer & Oncology Source Type: research

The Future Role of PET Imaging in Metastatic Breast Cancer
Background: A variety of therapeutic approaches are employed to treat patients suffering from breast cancer. Likewise, a broad spectrum of imaging ligands has been introduced for non-invasive PET/CT imaging to enable comprehensive tumor characterization and more accurate response evaluation. Summary: In recent years, novel radioactively labelled ligands have been developed for PET/CT imaging in metastatic breast cancer. One promising tracer is [18F]fluoroestradiol, which was recently approved by the Food and Drug Administration. It can be used for a whole-body assessment of estrogen receptor status. Another radionuclide c...
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation between VDR and Hr
This study aimed to explore the expression of VDR/Hr in breast cancer, and the correlation between VDR/Hr and prognosis, bone metastasis, and metastasis-related prognosis. Methods: The expression of VDR and Hr was performed on 119 breast cancer tissues and corresponding normal breast tissue from each of the breast cancer samples by Immunohistochemistry (IHC) staining, and the databases were supplemented as well. Results: The expression of VDR protein was significantly decreased in breast cancer patients (p 0.05) databases showed VDR mRNA expression tended to be higher in tumor tissues. Hr protein was expressed at low lev...
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care – a Randomized Pilot Study
Conclusions: Both SPC integration strategies were well accepted. However, patients seem not to benefit from a brochure in terms of initiating SPC counselling timely after a palliative cancer diagnosis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review
Conclusions: The BRAFV600E mutation may be a potential prognostic factor and therapeutic target for BC.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 24, 2021 Category: Cancer & Oncology Source Type: research

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Background: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients.Summary: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received a doublet or triplet combination as first-line therapy containing a proteasome inhibi...
Source: Oncology Research and Treatment - November 18, 2021 Category: Cancer & Oncology Source Type: research

Metronomic Chemotherapy for Metastatic Breast Cancer
Background: As disease control and quality of life play a leading role in metastatic breast cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside conventional chemotherapy (CCT) and targeted therapies.Summary: MCT, defined as continuous administration of low-dose chemotherapeutic agents, is accepted as a therapy that exerts its effects via immunomodulation, anti-angiogenesis and direct cytotoxic effects. Oral administration of MCT is safe, easy to handle, and allows for flexible drug dosing. Dose accumulations associated with non-tolerable side effects are rare, so the medication can be administered f...
Source: Oncology Research and Treatment - November 18, 2021 Category: Cancer & Oncology Source Type: research

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Background: Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2 decades, treatment paradigms substantially changed when novel drugs were introduced initially in treatment of relapsed disease and subsequently also in first-line treatment.Summary: Up to now, first-line treatment differs between patients initially classified as transplant eligible and those who are considered as nontransplant eligible. Transplant-eligible patients receive a primary proteasome inhibitor (PI)-based induction which is being combined with an immunomodulating agent and a CD38-directed monoclonal antibody follow...
Source: Oncology Research and Treatment - November 16, 2021 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: The Success Story Continues
Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 15, 2021 Category: Cancer & Oncology Source Type: research

Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy
Conclusions: BCRP/ABCG2 is highly expressed in hormone receptor-positive breast cancer. High BCRP/ABCG2 expression is associated with lymphatic metastasis, tumor size, and poor pCR. BCRP/ABCG2 may be a novel potential biomarker that can predict clinical progression and therapy response after neoadjuvant chemotherapy. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 12, 2021 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Background: Multiple myeloma is the second most common hematologic malignancy, which to date remains incurable despite advances in treatment strategies including the use of novel substances such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.Summary: The bone marrow-based disease is preceded by the 2 sequential premalignant conditions: monoclonal gammo ­pathy of undetermined significance and smoldering myeloma. Plasma cell leukemia and extramedullary disease occur, when malignant clones lose their dependency on the bone marrow. Key genetic features of these plasma cell dyscrasias include ch...
Source: Oncology Research and Treatment - November 8, 2021 Category: Cancer & Oncology Source Type: research

Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center
Conclusion In the present single center experience, a low serological prevalence of SARS-CoV-2 antibodies among cancer patients even after SARS-CoV-2 infection was found. The results support continued strict preventive measures as well as efforts towards faster vaccination, due to a low immunity level in the population. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research

Society Bulletins
Oncol Res Treat 2021;44:651 –658 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research

PharmaNews
Oncol Res Treat 2021;44:646 –650 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research

PharmaNews
Oncol Res Treat 2021;44:645 –645 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research

EC/GEJC: Adjuvante Immuntherapie erg änzt kurativen Behandlungsansatz
Oncol Res Treat 2021;44:642 –644 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - November 1, 2021 Category: Cancer & Oncology Source Type: research

Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
Background In metastatic breast cancer, blood-based diagnostics have become a major focus of oncological research in the last two decades. Detection of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) has the potential to improve prognosis assessment and complement standard therapy monitoring tools. Summary To date, several large analyses have confirmed high CTC counts as an independent prognostic factor. Persistently high CTC numbers during systemic treatment are associated with early progression but it remains to be clarified which therapeutic options should be offered to such patients since the SWOG 0...
Source: Oncology Research and Treatment - October 29, 2021 Category: Cancer & Oncology Source Type: research

Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer
Conclusions: Existing studies presented good clinic treatment effect about PT and TOMO for GC, and furthermore clinical studies are needed.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - October 25, 2021 Category: Cancer & Oncology Source Type: research

Routine Cancer Treatment Regimens and Its Impact on Fine Motor Dexterity in Breast Cancer
Conclusion: Our study showed that the extent of change in fine motor dexterity depends on the treatment regimen. The detection of unmet care needs could help to personalize and optimize clinical and survivorship care. Based on our findings, multidisciplinary support initiated early in breast cancer therapy is required.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - October 13, 2021 Category: Cancer & Oncology Source Type: research